Contact
Please use this form to send email to PR contact of this press release:
OSE Immunotherapeutics Presents its Novel Bispecific Checkpoint Inhibitor Platform, Targeting PD-1 and Innovative Targets at the 2019 World Immunotherapy Congress
TO: